🔥The 9th Round of Easy Loan, Earn $40 Reward is in progress❗️ ⏰ Promotion Period: January 15th - Feburary 15th, 2025 👉 Register now and check more details at gate.io/campaigns/358

ascopubs.org/doi/pdfdirect/…

Proud of my mentor Joshua Zeidner MD for his first-author #JCO publication and #EHA2025 presentation of AZA/VEN + REV in ND NPM1m/KMT2Ar AML with exciting early results! UNC Lineberger UNC Hematology-Oncology Fellowship leusm

#MDSsm docs- Phase 3 VERONA Trial for Higher-Risk MDS for Aza+Ven was not positive for its end point of OS . Does this mean you will 👇🏾Amer Zeidan MBBS,MHS ‏عامر زيدان Mikkael A. Sekeres MD, MS Naval Daver, M.D. David Steensma, MD David Swoboda, MD Joshua Zeidner MD

Leading the ongoing trial in older adults with NPM1-mutant or KMT2A-rearranged AML, Joshua Zeidner MD reports the addition of oral revumenib to azacitidine + venetoclax is safe and drives high remission rates, paving the way for a pivotal phase III. #AML ascopost.com/news/june-2025…

I think ddx state could be the next critical axis for stratifying AML. Beyond mutational data, this layer may guide tx selection, predict drug response, and one day serve as the basis for enrollment in ddx state–targeted trials. Inspiring work! Livius Penter

Fantastic overview of a VERY broad and controversial topic in AML therapy by Joshua Zeidner MD MD Education AML-ALL US Focus Meeting.